2020 is unlike any other year in recent history, with the global outbreak of the COVID-19 pandemic. The battle against the disease is one that’s shared among all nations and cities across the globe. However, we might be overlooking some of highly important public health agendas, such as chronic diseases which are worsened by the current situation.
As pointed by the International Diabetes Federation and supported by many other experts, people with diabetes can be more vulnerable to becoming severely ill with the COVID-19 virus.
The current pandemic can only be overcome by global societies sharing information transparently and developing innovative solutions together. Our on-going efforts to change the trajectory of the rise in diabetes via the Cities Changing Diabetes should not only continue but also take up more responsibility to alert our societies of the COVID-19 associated complications and risks for patients with diabetes.
The world’s leading cities of the CCD campaign have come together to share our initiatives and actions before and after the pandemic and to discuss how to face new challenges and risks and how to move forward with our combat against diabetes in our “new normal” situation.
Einar Jensen Danish Ambassador
Opening speech and presentation of Novo Nordisk CCD
Rana Azfar Zafar Country Manager of Novo Nordisk Pharma Korea
Why Collaboration Matters: The Cities Changing Diabetes Programme
Launched in 2015 as a collaboration between Novo Nordisk A/S, University College London, and the Steno Diabetes Center, Cities Changing Diabetes is now working with policymakers, community activists, academic leaders, and departments of health in 27 cities across the globe representing the healthcare needs of more than 150 million people. In this talk, Professor Napier will explain the background, purpose, and goals of the Cities Changing Diabetes Programme.
A. David Napier Professor of Medical Anthropology, University College London
Diabetes Status and Future Plans in Seoul
Seoul joined the Cities Changing Diabetes campaign in May 2019 and its ‘Mapping by Rule of Halves analysis for Seoul’ (comprehensive research project) was finished as of March 2020. In this talk, Professor Yoon will explain about the research design, its outcome and interpretation of the outcome. In addition, he will share plans to bending the diabetes curve through cooperation with stakeholders in various fields of Seoul in the future.
Kun-Ho Yoon Professor of Endocrinology and Metabolism, Seoul St. Mary’s Hospitals, The Catholic University of Korea & Chairman of Korean Diabetes Association
New Virtual Approaches Related to Patient Education
Copenhagen municipality has been actively engaged with the Cities Changing Diabetes with Steno Diabetes Center. Charlotte Glümer will explain about the status of diabetes in the city and introduce their new virtual approaches related to patient education.
Charlotte Glumer Director of Center for Diabetes, Municipality of Copenhagen
Cities Changes Diabetes (CCD) Busan- Continuous efforts over COVID-19
CCD Busan started just after launch in Seoul, last year. Because of COVID-19, no futher progress was achieved this year. Our efforts for co-work with Busan city will be continued. I would like to briefly show the baseline mapping data about the situation of diabetes in Busan city.
Jeong Hyun Park Professor of Endocrinology and Metabolism, Department of Internal Medicine, Inje University Busan Paik Hospital
Status and Outcome of Diabetes under the Covid-19 Pandemic in Daegu
Despite the fact that South Korea is well known for successfully responding to the Covid-19, the city of Daegu was hit most severely by the pandemic with a daily patients up to 741 (Feb 29th 2020) at its highest. Professor Kim will share how the pandemic changed the scene for patients and healthcare professionals. Professor Kim will explain the outcome of their mapping process and present recommendations for next steps.
Sung Woo Kim Assistant Professor of Endocrine and Metabolism of Internal Medicine, Daegu Catholic University Medical Center
Closing by Rana Azfar Zafar, Country Manager of Novo Nordisk Pharma Korea